Activation of the extraneuronal monoamine transporter (EMT) from rat expressed in 293 cells.
1. The extraneuronal monoamine transporter from rat (EMTr) was heterologously expressed by stable transfection in human embryonic kidney 293 cells and characterized in radiotracer experiments. 2. EMTr-mediated uptake of 1-methyl-4-phenylpyridinium (MPP(+)) was saturable, with a K(m) of 151 micro mol l(-1) and V(max) of 7.5 nmol min(-1) mg protein(-1). 3. Compared to the human orthologue EMTh (gene symbol SLC22A3), EMTr was about two orders of magnitude more resistant to most inhibitors, including disprocynium24 and corticosterone. 4. Strikingly, inhibitors and substrates at low concentration stimulated EMTr-mediated transport above control level with MPP(+) and noradrenaline as substrate, but not with cimetidine. Results were confirmed with EMT from mouse. 5. With different IC(50)-values for different substrates, the standard method to calculate K(i)-values is not applicable. 6. Our experiments suggest that activation is not caused by changes in membrane potential or trans-stimulation. Since the extent of activation depends markedly on the chemical structure of the monitored substrate, involvement of a receptor-mediated signalling pathway or recruitment of transporter reserve are implausible. 7. To explain activation, we present a kinetic model which assumes two binding sites for substrate or inhibitor per transporter entity, possibly resulting from the assembly of homodimers. 8. Activation explains previous reports about inhibitor-insensitive catecholamine transport in rat brain. 9. We speculate that activation may serve to keep the transporter working for specific substrates in the face of inhibitors.
Gründemann
Dirk
D
Department of Pharmacology, University of Cologne, Gleueler Strasse 24, 50931 Cologne, Germany. dirk.gruendemann@uni-koeln.de
Koschker
Ann-Cathrin
AC
Haag
Christine
C
Honold
Cornelius
C
Zimmermann
Tim
T
Schömig
Edgar
E
D015655:1-Methyl-4-phenylpyridinium / Q000493:pharmacokinetics; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002460:Cell Line; D002927:Cimetidine / Q000493:pharmacokinetics; D003001:Cloning, Molecular; D003345:Corticosterone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015870:Gene Expression; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D007700:Kinetics; D051379:Mice; D009638:Norepinephrine / Q000493:pharmacokinetics; D027701:Organic Cation Transport Proteins / Q000235:genetics / Q000378:metabolism*; D010208:Papaverine / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D013890:Thiourea / Q000031:analogs & derivatives* / Q000494:pharmacology; D014162:Transfection; D014316:Tritium; D000099254:Organic Cation Transporter 3
D015655:1-Methyl-4-phenylpyridinium; D002927:Cimetidine; D003345:Corticosterone; D007093:Imidazoles; D009638:Norepinephrine; D027701:Organic Cation Transport Proteins; D010208:Papaverine; D010880:Piperidines; D011804:Quinolines; D013890:Thiourea; D014316:Tritium; D000099254:Organic Cation Transporter 3; C103851:disprocynium 24; C085755:4-(1H-imidazol-4-ylmethyl)piperidine; C052075:thioperamide; C086108:clobenpropit